Yarrow Bioscience, Inc. (YARW) stock
Close on Nov 13, 2026Market cap $206.86MP/E –Yield –
Yarrow Bioscience, Inc. grew revenue 13.8% to $570.00K over fiscal 2025. Free cash flow was -$33.12M. At the latest close the market valued the company at $206.86M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $206.86M
- P/E ratio
- –
- Price to sales
- 362.92
- Price to book
- 0.77
- Dividend yield
- –
- Free cash flow yield
- -16.01%
Fundamentals
- Revenue
- $570.00K
- Net income
- -$26.48M
- EPS, diluted
- -$31.00
- Free cash flow
- -$33.12M
- Book value per share
- $11.84
- Diluted shares
- 23M
Trading
- Previous close
- $19.63
- Open
- $19.33
- Day's range
- $17.99 – $19.86
- Volume
- 99,112
- Average volume (20 days)
- 190,418
- Beta (5 years)
- 1.55
- 52-week range
- $12.38 – $46.95
- RSI (14 days)
- 46.3
- Volatility (1 year)
- 94.0%
- Relative volume
- 0.88×
- WACC
- 12.8%
On 3 of our idea lists: Net-nets, More cash than they're worth, Yields that look too good (a warning list)
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | YARW | S&P 500 | Difference | YARW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | -3.0% | −0.0 pts | ||
| 3 months | -57.8% | -2.8% | −55.0 pts | ||
| Year to date | +10.2% | +11.5% | −1.3 pts | ||
| 1 year | +73.1% | +13.5% | +59.6 pts | ||
| 3 years | -81.6% | +77.7% | −159.3 pts | -43.2% | +21.1% |
| 5 years | -97.3% | +72.6% | −169.9 pts | -51.3% | +11.5% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Yarrow Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Results
About Yarrow Bioscience
Pharmaceutical Preparations
VYNE is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immune-mediated conditions with high unmet medical needs. The company focuses on small molecule bromodomain and extra-terminal domain BET inhibitors, specifically through its InhiBET platform. Its pipeline includes VYN202, an oral BD2-selective inhibitor under evaluation for various autoimmune and inflammatory disorders, and repibresib, a topical pan-bromodomain inhibitor. Because its drug candidates remain in clinical development, the company does not yet sell commercial products to end consumers, but its research targets patients afflicted with serious inflammatory conditions.
Company profile, executives and historyYarrow Bioscience stock: common questions
What is Yarrow Bioscience's stock price?
YARW closed at $18.03 on Nov 13, 2026, down 8.15% on the day. Over the past 52 weeks it traded between $12.38 and $46.95.
What is Yarrow Bioscience's market cap?
Yarrow Bioscience was worth $206.86M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is YARW's P/E ratio?
Yarrow Bioscience lost money over fiscal 2025 (diluted EPS -$31.00), so it has no meaningful P/E ratio.
How much revenue does Yarrow Bioscience make?
Yarrow Bioscience reported revenue of $570.00K for fiscal 2025, up 13.8% from a year earlier.
Does Yarrow Bioscience pay a dividend?
No. Yarrow Bioscience has not paid a cash dividend over the last twelve months.
How has YARW stock performed over the past year?
Including dividends, YARW returned +73.1% over the past year, against +13.5% for the S&P 500.
How many YARW shares are sold short?
0M shares were sold short at the latest FINRA report, 1.53% of the float, or 1.0 days of average trading volume.
Who are Yarrow Bioscience's competitors?
Companies most similar to Yarrow Bioscience by business, industry and size include RLYB, STTK, DNTH, VCNX, CANF.
See a number that looks wrong?